Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer. Wit ...

ORANGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2024 financial results on Thursday, Feb. 27, 2025, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the followi ...

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM Location: Virtual A live webcast of ...

PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 4, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

First Focal One® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer CenterOnQ Prostate’s Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists performing Focal One Robotic High Intensity Focused Ultrasound (HIFU) ablation Reflects EDAP’s continued commitment to innovation and further validates Focal One as the leading focal therapy platform con ...

PITTSBURGH, Feb. 6, 2025 /PRNewswire/ -- Koppers Holdings Inc. (NYSE: KOP), an integrated global provider of treated wood products, wood treatment chemicals, and carbon compounds, today announced that the company plans to release its financial results for the fourth quarter and full-year 2024 before the market opens on Thursday, February 27, 2025, and discuss its outlook on a conference call later that day at 11:00 a.m. Eastern Time.  Presentation materials will be available at least 15 minutes before the c ...

Moelis & Company (MC) shares gained 2.9% in after-hours trading following the release of its better-than-expected fourth-quarter and full-year 2024 results. Adjusted earnings for the quarter of $1.18 per share surpassed the Zacks Consensus Estimate of 46 cents by a huge margin. The bottom line improved from a loss of 6 cents per share in the prior-year quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Results benefited from a rise in revenues and other income. Also, the compan ...

Over the years, Mastercard (MA 1.28%) has done nothing but reward its investors. Since the company's initial public offering (IPO) in May 2006, shares have skyrocketed, rising 12,160% (as of Feb. 3). A $1,000 investment would be worth $122,600 today.That gain is hard to overstate. Even these days, Mastercard continues to put up strong financial results. For prospective investors, is this top financial stock still a buy?Growing the top and bottom lineInvestors will appreciate Mastercard's ability to steadily ...

Acute Agitation and Aggression Treatment Market is set for significant growth from 2024 to 2034, driven by the rising prevalence of psychiatric disorders and advancements in treatment approaches. Key therapies include First-Generation Anti-Psychotics (Chlorpromazine, Haloperidol), Second-Generation Anti-Psychotics (Quetiapine, Olanzapine, Ziprasidone), Benzodiazepines (Lorazepam, Midazolam), Alpha-2 Adrenergic Agonists (Clonidine, Dexmedetomidine), and Others (Droperidol, etc.). Increasing adoption of fast- ...

NETGEAR, Inc. (NTGR) reported fourth-quarter 2024 non-GAAP loss per share of 6 cents, which was significantly narrower than the Zacks Consensus Estimate of a loss of 25 cents. The company had reported non-GAAP earnings of 9 cents in the year-ago quarter. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.NETGEAR generated net revenues of $182.4 million, beating the consensus estimate by 8.9%. The figure also beat the guidance of $160-$175 million. Revenues were down 3.3% on a year-over ...